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Abstract
Background and Objective: Myristicin belongs to a class of potentially toxic chemicals (alkoxy substituted allylbenzenes) and despite
the structural analogy with safrole, data on this compound are very controversial and unclear. In this study assessed the cytotoxic and
genotoxic potential of myristicin and 1’-hydroxy-myristicin after 24 h of exposure in HepG2 cells. Methodology: The compounds were
tested  up  to  600 µM concentration, for 24 h. The genotoxicity was assessed with alkaline and neutral comet assay and micronucleus
assay.  The  data  were  analysed  by  one-way  ANOVA.  Results:  It  is  to  be  emphasized  that  only  the  synthetic  Phase  1  metabolite
(1’-hydroxymyristicin) showed a genotoxic effect starting from the concentration of 150 µM both in comet and micronucleus tests.
However,  it  is  important  to  point  out  that  the  same  concentration  cause  a  statistically  significant  (p<0.001)  apoptotic  process.
Conclusion: The consumption of a traditional diet determines very low levels of exposure to the parent myristicin. This fact implies as the
primary metabolic pathway the O-demethylation (5-allyl-2,3-dihidroxyanisole) and not to Phase I metabolism, which leads to the
conclusion that this substance could not present a significant risk to humans.
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INTRODUCTION
Myristicin is an alkoxy-substituted allylbenzene
(alkenylbenzene) present in a variety of botanical species such
as fennel, parsley, carrot, parsnip, basil, anise, dill, celery and in
some spices consumed by humans, such as nutmeg, macis,
cinnamon and clove. Myristicin is also found in some food
additive oils or in traditional medicine1,2.
In the last year's, the consumption of botanical and
botanical ingredients has increased, due to the fact that they
are used as plant food supplements with the aim of enhancing
health. Usually, plant food supplements and phytochemicals
are considered safe because of their natural origins3. This
assumption is not correct because it is known that some
herbal preparations can contain individual potential harmful
chemicals, among which are alkylbenzenes, in particular,
allylalkoxybenzenes, with toxic and well known genotoxic
properties4-6. Special attention has been given to estragole,
methyl eugenole and safrole since, although, at very high
levels of exposure, they were found to be genotoxic and
carcinogenic  in  animals7,8.  The  genotoxic  potential  of
myristicin is still questioned even if there are overall evidence
that it produces DNA adducts albeit in smaller quantities and
less persistent than estragole, safrole and methyleugenol9,10.
The  compound  shows  neither  mutagenic  activity  in
Salmonella typhimurium TA100 and TA98 at up to cytotoxic
doses with and without metabolic activation nor UDS
(Unscheduled DNA Synthesis) in hepatocytes from male fisher
34411,12. The discrepancy emerged from in vivo  and in  vitro
experiments, could likely be a different ability of DNA damage
repair activity in the models considered. Myristicin induces
apoptotic death in human neuroblastoma SK-N-SH cells
accompanied by an accumulation of cytochrome c and by
activation of caspase 313. More evidence of apoptosis
induction   were   observed   in   a   study   in   hamster   ovary
CHO cells2 and, more recently, a study revealed that myristicin
induces apoptosis in human leukemia K562 cells14, besides
changes in the mitochondrial membrane potential, the release
of  cytochrome  c, activation of caspase 3 and cleavage of
PARP and DNA fragmentation. Furthermore, the same study
showed that myristicin down-regulated genes involved in
DNA damage response pathways, such as genes for the
nucleotide excision repair, the double strand break repair, the
DNA damage signaling and stress response14.
Alkenylbenzenes can undergo different metabolic
pathways (Fig. 1). It is reported in the literature that a notable
increase in the formation of the 1’-hydroxy metabolites occurs
after an increase in dose of the parent compound, which is
accompanied   by   a   shift   in   metabolic   pathways15,16.   This
metabolite can then become the substrate of sulfotransferase
enzymes, going through a reaction of esterification. The
esterified metabolite can dissociate and give the reactive
carbocation, able to link nitrogenous bases forming adducts
with DNA. In human hepatic cells (HepG2), it is evident that
myristicin yields DNA adducts quantitatively equivalent to that
of safrole17.  The  aim of this  work  is  to  study  the  in  vitro
cyto-genotoxicity    of    myristicin    and    1’-OH    myristicin
(Fig. 1), using a metabolically active model of human
hepatoma  cell  line  (HepG2)  and  believes  that  more
information is needed to obtain sufficient data for a correct
risk assessment.
MATERIALS AND METHODS
Chemicals and reagents: The RPMI-1640 medium, pyruvic
acid,       L-glutamine,       penicillin-streptomycin       solution,
3-(4-5-dimethylthiazol-2-1l)-2,5-diphenyl tetrazolium bromide
(MTT),  Neutral  red  solution  (0,33%),  dimethyl  sulfoxide
(DMSO), trypsin-EDTA solution 1X, low-melting point agarose
(LMA), agarose for routine use, propidium iodide (1mg mLG1 in
water),  sodium  chloride  (NaCl),  tris  (hydroxymethyl)
aminomethane, sodium hydroxide (NaOH), potassium chloride
(KCl), Triton X-100, hydrochloric acid (HCl), sodium-citrate,
citric acid and sucrose were obtained from Sigma-Aldrich,
Italy.  Fetal  bovine  serum  (FBS),  Sytox  green  and  6 µm
fluorescent beads were purchased from Invitrogen Life
technologies (Italy).
Myristicin was purchased from Sigma-Aldrich (Milan, Italy)
while 1’-hydroxymyristicin was synthesized and provided from
Division of Toxicology, Wageningen University (Wageningen,
The Netherlands).
Myristicin and 1’-hydroxymyristicin both were dissolved
in DMSO and solutions obtained were dissolved 1:1000 in
RPMI-1640 medium (Fig. 1).
Cell cultures: HepG2 cells, a human hepatocellular carcinoma
cell line,  were purchased from Istituto zooprofilattico (Brescia,
Italy). Cells were maintained in RPMI-1640 medium added with
10% of  heat inactivated FBS, 0.01% of pyruvic acid, 0.03% of
L-glutamine and 1% penicillin-streptomycin solution and
placed  at  37EC,  under  humidified  air  supplemented  with
5% CO2.
Confluent   monolayers   were   exposed   to   myristicin
(600   µM)    or    1’-hydroxymyristicin concentrations    (from
50-600 µM) in RPMI-1640 medium for 24 h at 37EC.
Cytotoxicity assessment
MTT   assay:   This   assay   was   conducted   according   to
Schiller  et  al.18,  HepG2  cells  were  grown  in  a  96-well  plate,
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Fig. 1: Proposed metabolic pathways of the alkenylbenzene myristicin15
myristicin or 1’-hydroxymyristicin were added and then
removed after 24 h. MTT dye (final concentration 0.5 mg mLG1)
was added to each well. After removal of MTT solution, cells
were lysed with 150 µL of DMSO in order to dissolve the
formazan crystals. The plate was read at 550 nm with the
spectrophotometer (Multilabel counter Victor Wallace 1420,
Perkin-Elmer, Italy) and absorbance was determined. Samples
with a cell viability less than 50% were subsequently excluded
from genotoxicity analysis.
Neutral red assay: The neutral Red assay was based on
Rodrigues method19. HepG2 cells were grown in 96-well plates
and  subsequently  treated.  Then  plates  were  washed  with
PBS and 200 µL of the neutral red solution, 25 µg mLG1 in the
culture  medium,  were  added  to  each  well  after  a
centrifugation at 5000 rpm for 5 min. Neutral red (0.33%) was
dissolved in culture medium the day before the test and left at
37EC during the night. The day of the test, plates with neutral
red solution was incubated at 37EC for 3  h  and then cells
were  rinsed  with  PBS  and  lysed  with  a  solution  containing
citric acid, ethanol and water (1:50:49), in order to let neutral
red going out from lysosomes. After 30 min of agitation, plates
were read at 550 nm with the spectrophotometer (Multilabel
counter Victor Wallac1420, Perkin-Elmer Italy) and absorbance
was determined. The absorbance measured correlates with
the  number  of  living  cells  for  each  well,  considering  that
each sample is referred to the negative control to which is
attributed a 100% cell viability. Samples with a cell viability
less than 50% were excluded from genotoxicity analysis.
Apoptosis evaluation (Annexin v assay): This assay measures
a number of cells that are going toward an apoptotic process,
differentiating in early and late stages of this mechanism.
Annexin V is a human protein Ca2+ dependent that for this
assay is labeled with a fluorophore. Annexin V has a high
affinity for phosphatidylserine (PS), a phospholipid that
normally stays on the cytoplasmic surface of cell membrane
and that during apoptosis is translocated on the outer side of
the membrane, becoming able to be linked by Annexin V. The
test was performed with Alexa Fluor 488  Annexin  V/Dead  cell
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apoptosis Kit (Invitrogen). Cells were seeded 24 h before
treatment in 60 mm plates at a density of 6.5×105 cells mLG1.
After  treatment,  cells  were  collected  with  trypsin  and
centrifuged for 5 min at 2000 rpm. Cells are then suspended
in 1 mL of PBS+5% FBS and counted with trypan blue. A
volume of 106 cells mLG1 is calculated for each sample and cells
are subsequently combined with 100 µL annexin binding
buffer  0.5x.  Annexin binding buffer 0.5x was obtained with
Na citrate (0.1% ) Then 5 µL of Annexin V were added to each
sample and finally also 1 µL of working solution (propidium
iodide dissolved 1:10 in ABB 0.5x) was added to each sample.
Samples were left  at  RT  in  the  dark  for  15  min.  In  the  end,
400 µL of ABB 1:10 were added and samples were read in flow
cytometry at a wave length of excitation of 496 nm with an
emission of 519 nm. Results are expressed as apoptotic cells
percentage for each sample.
Genotoxicity evaluation
Alkaline comet assay: Experiments were carried out
according to Singh et al.20., HepG2 cells were plated in 60 mm
culture dishes and after 24 h they were exposed to studied
compounds. Then the cells were collected with trypsin and
centrifuged  at  2000  rpm  for  5  min.  Pellet  was  suspended
in 1 mL of culture medium with a 20 G syringe needle. A total
of  2×104  cells  mLG1  were  suspended  in  200  µL  of  0.5%
low melting  point agarose (LMA) in PBS and then transferred
onto  pre coated microscope slides with 1% agarose for
routine use in PBS and covered with a cover glass. Slides were
stored at 4EC for 10 min, then cover glass was removed and
the second layer of LMA was added to each slide. After 10 min
at  4EC,  slides  were  immersed  in  lysis  solution  (2.5  M  NaCl,
100  mM  Na-EDTA,  10  mM Tris,  250  mM NaOH,  10%  DMSO,
1% Triton X-100, pH 10) at 4EC for 1 h. Slides were then rinsed
with neutralization solution (0.4 M Tris, pH 7.5) and placed in
a horizontal gel electrophoresis tank (PBI) filled with ice-cold
electrophoresis buffer (0.3 M NaOH, 1 mM Na-EDTA, pH>13)
and left this way for 35 min, in order to let DNA unwinding.
Then electrophoresis run was done at 300 mA for 45 min,
followed by 5 min of neutralization with neutralization
solution and finally, slides were fixed with ethanol at -20EC for
5 min. Slides were left to dry at room temperature and then
nuclei were stained with propidium iodide (20 µg mLG1 in
water) and analyzed using fluorescence microscope (Axioplan
2, Zeiss, Milan, Italy) at 25-fold magnification. For each sample,
at least 100 randomly selected nucleoids were examined.
Images of nucleoids were analyzed with TriTek Comet Score
Imaging software 1.5 and tail length, tail moment and % of
DNA in the tail were measured. Moreover, nucleoids were
classified into 5 different categories  according  to  area,  shape
and intensity of fluorescence of their tail.(A: normal nucleoid,
B, C, D: damaged nucleoids, E: ghosts).
Neutral comet assay (NRA): Slides with a layer of lysed cells
and LMA were placed in the horizontal electrophoresis tank
with  a  buffer  (pH  8.3)  containing  90  mM  Tris,  2  mM 
EDTA, 90 mM boric acid and left this way for 15 min before
starting the electrophoretic run at 80 mA for 25 min. Nucleoids
were stained with propidium iodide (20 µg mLG1 in water) and
analyzed   using  fluorescence  microscope  (Axioplan  2)  at
25-fold magnification20.
For each sample, at least 100 randomly selected nucleoids
were examined. Images of nucleoids were analyzed with
TriTek Comet Score Imaging software 1.5 and tail length, tail
moment and % of DNA in the tail were measured.
Micronucleus assay: Experiments were done according to
Bryce et al.21, making an analysis of micronuclei in flow
cytometry, associated also with a measure of cell viability
through fluorescent microspheres (beads). Cell viability
measure made through fluorescent beads is considered more
accurate than measure obtained with normally used
cytotoxicity assays, which can overestimate a number of living
cells. The day before treatment, cells were seeded at a density
of 6.5×105 cells mLG1. After treatment, a period of 24 h
followed in which cells were left in the medium at 37EC, in
order to give time to have cell division. The day of the
experiment, cells were collected and centrifuged for 5 min at
2000 rpm, then each sample was suspended in 1 mL of
PBS+2% FBS and counted by trypan blue method, in order to
obtain a quantity of 5×105 cells mLG1 for each sample.
Calculated volume was suspended in PBS+2% FBS in order to
reach a total volume of 1 mL for each sample. After 5 min of
centrifugation, 300 µL of propidium iodide (2 µg mLG1) were
added to each tube and samples were left in the dark at real
temperature for 10  min. Samples were centrifuged and pellets
were suspended in 1 mL of PBS+2% FBS, after another
centrifugation of 2000 rpm for 5 min,  pellets  were  left  in  the
dark  at  RT  for  30  min  with  just  50  µL  of  supernatant
covering them. Then 500 µL of Lysis 1 solution (0.584 mg mLG1
NaCl,  1.13  mg  mLG1  Na-citrate,  0.3 µL  mLG1  IGEPAL©CA630,
0.5 mg mLG1 RNAse, 0.4 µM Sytox Green) were added to each
sample. After 1 h at RT in the dark, 500 µL of Lysis 2 solution
(85.6 g mLG1 sucrose, 16.4 mg mLG1 citric acid, 0.4 µM Sytox
Green, 2 drops mLG1 beads) were added to each sample. After
at least 30 min in the dark at RT, samples were transferred to
FACS tubes and stored at 4EC until flow cytometry analysis.
MN number was determined through the acquisition of at
least 20,000 gated nuclei for each sample  and  it  is  expressed
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 as fold increase respect negative control. Fold increase >3 was
considered a positive result for this test. Nuclei/beads ratio
was determined for each sample and referred to that of
negative control, in order to have an evaluation of relative cell
survival.
Statistical analysis: Triplicate experiments were performed
with independent samples. The results were analyzed using
ANOVA t-test to assess statistical significance,  one-way  or
two-way ANOVA analysis followed by post-hoc  Dunnett
results were considered statistically significant at p<0.05.
Analysis was carried out using the software package GraphPad
Prism version 6.0 (GraphPad Prism Software Inc., La Jolla USA).
Statistical differences were considered at the p<0.05, p<0.01
or p<0.001 level vs. the control group as indicated in the
figures and captions. In the following, the results are
expressed as means±standard deviation.
RESULTS
MTT     and     NRA:     Concentrations     of      myristicin     and
1’-hydroxymyristicin suitable to conduct reliable genotoxicity
studies were established on the basis of concentrations that
did not cause a reduction of more than 50% cell viability Cells
exposed to myristicin (range 50-600 µM) for 24 h did not show
a  significant cell  viability  reduction,  both  with  MTT  and
NRA up to 600 µM (data not shown). Differently, cells exposed
to 1’-hydroxymyristicin, at the same range of concentrations,
showed a dramatic viability reduction (p<0.001) starting from
150  µM  in  MTT  test  and  from  50 µM  concentration  in  NRA
(Fig. 2). The MTT and NRA dose-response were very similar.
Alkaline comet assay (pH>13)
Myristicin: Cells were exposed for 24 h to 450 and 600 :M
myristicin concentration (Fig. 3). None of the parameters
showed a significant difference in respect to control.
1’-Hydroxymyristicin:   Cells   were   exposed   for   24   h   to
50-450 :M concentrations of 1’-hydroxymyristicin (Fig. 4a-c).
Tail  moment  and  nucleoids  classification  showed  a
significant   p<0.05   difference   between   cells   exposed   to
1’-hydroxymyristicin  450  µM  and  non-treated  cells.  A
significant p<0.05 increase was measured in the percentage
of nucleoids category (A, B, C and D damaged) from 150 :M
and above (Fig. 4a-c).
Neutral comet assay (pH 8): Using the neutral version of
comet   assay   that   identifies    double    strand    damage,    a
Fig. 2(a-b): Cytotoxicity  evaluation,  through  MTT  and
Neutral  red  assay  in  HepG2  cells   exposed   to
1’-hydroxymyristicin for 24 h
Data are elaborated through one-way ANOVA (Dunnett’s  post
hoc  test) analysis. Means±Standard deviation, ***p<0.001 vs.
vehicle, DMSO 0.1%
significant p<0.05 dose-response increase of DNA damage has
been observed only in cells exposed to 1’-hydroxymyristicin,
150 and 450 µM (Fig. 5a, b). In this test, the parameters
normally utilized are tail length and tail moment. These results
supported the increase of nucleoids E (see alkaline comet
assay  results)  and  the  reduction  of  viability  already
highlighted.
Micronucleus assay: The increase of micronucleus frequency,
detecting the presence of damaged chromosomes in cells
after division, confirms the extent of DNA damage observed in
the comet assay (alkaline and neutral test). As shown in Fig. 6,
cells exposed only to 150 and 450 µM 1’-hydroxymyristicin
showed a marked increase in the number of micronuclei
largely exceeding the threshold level (n = 3) for this test. The
decrease of the effect at 450 µM 1’-hydroxymyristicin likely
due to the cytotoxicity (Fig. 2).
No   genotoxic   response   was   elicited   by   myristicin
(600 µM).
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Fig. 3(a-c): Evaluation of genotoxic damage by alkaline comet test (pH>13) in HepG2 cells exposed to myristicin (450-600 µM)
for 24 h
Data are elaborated through one-way ANOVA (Dunnett’s post  hoc  test) analysis, (a) Tail moment (µm),  (b) % BCD nucleoids and (c) % E nucleoids 
Means±Standard deviation, **p<0.01, ***p<0.001 vs C-,vehicle (DMSO 0.1%), C+ positive control (mitomycin 0.1 µg mLG1)
Annexin v assay: The cytotoxicity and the type of DNA
damage have led us to investigate a possible apoptotic effect
associated with 1’ hydroxymyristicin treatment.
A significant increase (p<0.01 and p<0.001) in apoptotic
cell numbers (both in early Fig. 7a  and late apoptotic stage
Fig. 7b and therefore not only as phosphatidylserine (PS)
expression on the outer leaflet membrane but also as a
triggered   apoptotic   process),   was   actually   observed   in
cells     exposed    to    concentration    of    150   and   450   µM
1’-hydroxymyristicin (Fig. 7a and b).These evidence support
the results previously obtained with alkaline comet assay
(Nucleoids E) and also with MTT and NRA.
DISCUSSION
Toxicity of allylbenzenes, constituents of a variety of
botanical based food, is strongly dependent on the presence
of functional groups that may influence the chemical reactivity
accordingly, the biological activity of these natural
constituents. The allylbenzene family is very diversified by the
presence    or    absence    of    alkylation    products    of    their
para-hydroxyl substituents, and/or position of the double
bond in the alkyl side chain. Besides this, also minor structural
variations may elicit differences in bioactivation/detoxification
pathways that can affect the toxicological assessment. This
becomes relevant when considering the formation of reactive
metabolites. In the scientific literature, there are conflicting
data on the toxicity of allylalkoxybenzenes (myristicin,
estragole, methyl eugenol and safrole), propenyl
alkylbenzenes (anethole,  isoeugenol methyl ether), 
allylhydroxybenzenes (chavicol  and  eugenol)  and  propenyl
hydroxybenzenes (isochavicol and isoeugenol)7.
While  estragole,  methyl eugenol,  safrole and  anethole
have proved to be hepatotoxic, genotoxic and carcinogenic,
the genotoxic and possibly carcinogenic potential of
myristicin   at   equivalent   doses  is  not  to  be  expected.
Dose-dependent formation of protein and DNA adducts in
liver22-29 was observed with allyl alkoxy benzenes. Although
DNA adducts in the liver of CD1 female mice were isolated, the
binding of myristicin to mouse-liver DNA was weaker than
those of other compounds such as safrole, estragole and
methyleugenol10.
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Fig. 4 (a-c): Evaluation  of  genotoxic  damage  by  alkaline  comet  test  (pH>13)  in HepG2 cells exposed to 1’-hydroxymyristicin
(50-450 µM) for 24 h
Data are evaluated through one-way ANOVA (Dunnett’s post  hoc  test) analysis, (a) Tail moment (µm), (b) % BCD nucleoids and (c) % E nucleoids
Means±Standard deviation, *p<0.05, **p<0.01, ***p<0.001 vs C-,vehicle (DMSO 0.1%), C+ positive control (mitomycin 0.1 µg mLG1)
Fig. 5(a-b): Neutral  Comet   test   (pH   8)   evaluation   in   HepG2   cells   exposed    to    1’-hydroxymyristicin    (50-450    µM)    for 
24 h
Data are evaluated trough one-way Anova (Dunnett’s post  hoc  test) analysis, (a) Tail length (µm) (b) Tail moment (µm), Means±Standard deviation,
*p<0.05, **p<0.01 vs C-, vehicle(DMSO 0.1%)
This study tries to clarify the genotoxic potential of
myristicin,  one  of  the  constituents  of  nutmeg  powder,  to
which diverse populations are exposed through food and
beverages. The human hepatoma line (Hep G2) has retained
the activities of various Phase I And Phase II enzymes which
play a crucial role in the activation/detoxication of genotoxic
procarcinogens30. No carcinogenicity studies of myristicin in
animals   were   available   in   the   literature.   Miller   et   al.25,26,
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Fig. 6: Evaluation of genotoxic damage through micronucleus
test     in    HepG2   cells   exposed   to   myristicin   and
1’-hydroxymyristicin
Detection of micronuclei is made in flow cytometry, C+positive control
(mitomycin 0.1 µg mLG1). Micronuclei values are expressed  as  fold 
increase  respect  negative  control  (value  of  1 on Y axis). A fold
increase >3 gives an indication of positive results. Means±Standard
deviation
Fig. 7(a-b): Evaluation of apoptotic cells by Annexin V test in
HepG2   cells   exposed   to  1’-hydroxymyristicin 
for 24 h
Data are elaborated through one-way Anova (Dunnett’s post  hoc 
test) analysis,   (a)   Percentage   of   early   apoptotic    cells   and
(b) Percentage of late apoptotic events, Means±Standard
deviation, ***p<0.001, **p<0.01, vs C-, vehicle (DMSO 0.1%). C+,
positive control (staurosporine 8.56 µM)
performed comprehensive sets of bioassays to characterize
the hepatocarcinogenic potential of naturally occurring and
synthetic alkylbenzene derivatives including myristicin and its
metabolites, intraperitoneally treatment of male B6C3F1 mice
24 h after birth and at days 8, 15 and 22 for a total  dose  of
4.75  µmol/mouse   did   not   show   carcinogenic   effects   at
13 months.
The  genotoxic  potential  of  alkoxy-substituted
allylbenzenes is likely due to the CYP-catalysed formation of
the  1’-hydroxy  metabolite  and  subsequent  activity  of
sulfotransferase 1A1 (SULT1A1), that catalyses the formation
of the 1’-sulfoxy conjugate. Myristicin  in  vivo,  in the range of
human food intake, may metabolically be converted mainly by
CYP1A1 and 2A6 to epoxy- or hydroxy-derivatives that
undergo glucuronidation and are readily excreted. At high
doses in rodents, O-demethylation becomes saturated and
then  takes  place  1’-hydroxylation  and  epoxidation  of  the
allyl side-chain. This change in the balance of metabolic
pathways, at high doses, leads to a predominant formation of
1’-hydroxy-metabolites  and  the  subsequent  formation   of
1’-sulfoxy metabolites by SULT 1A1 and SULT 1C2 that have
been associated with the genotoxicity and carcinogenicity7,31.
The unstable sulfate ester forms a reactive electrophilic
intermediate (carbonium ion or quinolinium cation), which
binds  to  proteins  and  DNA.  Sulfate  inhibition  studies  and
in vivo-in  vitro  unscheduled DNA synthesis (UDS) assays of
myristicin,   elemicin,   estragole,   methyl   eugenol   and   the
1’-hydroxy metabolites of estragole and methyl eugenol12,21,32
provide  additional  evidence  that  the  sulfate  ester  of   the
1’-hydroxy metabolite is the ultimate toxic metabolite in
animal. Data related to the safety of estragole and safrole,
structurally related to myristicin, indicate that at low dose
levels (below 1-10 mg kg b.wt., in rodents and humans),
allylalkoxybenzenes are  rapidly  cleared  from  the  body,  with
O-demethylation being the major metabolic route. Metabolic
shifting from O-demethylation to 1’-hydroxylation results in
increased formation of 1’hydroxymetabolite and accordingly
of the toxic reactive electrophilic 1’-sulfoxy conjugate
metabolite at higher dose level (30-300 mg kg b.wt.,)31.
Our data showed no genotoxic potential of myristicin in
comparison to other alkenylbenzenes with similar structures
(safrole, estragole)33,34. Besides, myristicin does not elicit any
cytotoxicity differently from its 1’hydroxymetabolite that
elicited cytotoxic, genotoxic and apoptotic effects from a
concentration of 150 µM. The appearance of the apoptotic
effect must be considered because it can mask the genotoxic
effect. It is also evident that 600 µM myristicin in our
experimental   conditions   does   not   generate   a   sufficient
1’-hydroxymyristicin quantity to give the final toxicant
product.
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CONCLUSION
Our data confirms that there was no genotoxic potential
of myristicin. The fact that only hydroxyl metabolite is
genotoxic in a narrow range of doses, underlines that the
mechanism of carbocation formation (1’-sulfoxy conjugate
toxic  metabolite  production)  is  necessary  for  genotoxic
activity.
This is an important point to consider in the risk
assessment of dietary exposure to myristicin, which is mainly
carried through consumption of the spices nutmeg and mace
and of non alcoholic beverages. The average exposure for
myristicin may be as high as to 162 µg/day (3/684 µg/day
lower and upper limits equal to 0.05 and 11.4 µg kgG1
b.wt.,/day, respectively for an adult of the average weight of
60 kg) in Europe. The results lead to the conclusion that
myristicin presents no significant risk to humans through
consumption of a traditional diet because the very low levels
of exposure. The low doses cause essentially the primary
involvement of the O-demethylation leading to a safer
metabolic path.
SIGNIFICANCE STATEMENTS
This study shows that data concerning to alkenylbenzene
compound are limited and inconsistent. This study provided
additional information regarding the myristicin genotoxicity
and its metabolism.
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